<DOC>
	<DOCNO>NCT01661335</DOCNO>
	<brief_summary>The purpose study find whether add aprepitant ( Emend® ) standard therapy help child receive chemotherapy less nausea vomiting .</brief_summary>
	<brief_title>Efficacy Aprepitant ( Emend® ) Children</brief_title>
	<detailed_description>1.1 Primary Aim To determine efficacy aprepitant ( Emend® ) prevent reduce chemotherapy-induced nausea vomiting ( CINV ) add standard antiemetic drug regimens child receive highly emetogenic chemotherapy . The work hypothesis standard therapy + aprepitant superior prevent CINV standard therapy + placebo . 1.2 Secondary Aim To evaluate safety toxicity aprepitant ( Emend® ) child receive highly emetogenic chemotherapy compare standard antiemetic therapy + placebo .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Antiemetics</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>20.99 year age enrollment Scheduled receive two identical cycle highly emetogenic [ 1 ] chemotherapy treatment primary malignancy , include : Chemotherapy one follow single agent combination : Carboplatin Carmustine &gt; 250 mg/m2 Cisplatin Cyclophosphamide ≥1 g/m2 Dactinomycin Or follow defined combination : Cyclophosphamide + anthracycline Cyclophosphamide + etoposide Cytarabine 150200 mg/m2 + daunorubicin Cytarabine 300 mg/m2 + etoposide Cytarabine 300 mg/m2 + teniposide Doxorubicin + ifosfamide Doxorubicin + methotrexate 5 g/m2 Etoposide + ifosfamide Patients receive aprepitant past . Patients demonstrate evidence increase intracranial pressure .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Nausea</keyword>
	<keyword>Vomiting</keyword>
	<keyword>Children</keyword>
	<keyword>Aprepitant</keyword>
	<keyword>Emend®</keyword>
</DOC>